摘要
Abstract
Objective:To explore the characteristics and patterns of endocrine adverse drug reaction(ADR)induced by sintilimab,providing references for clinical safe medication.Methods:Case reports of the endocrine system ADR induced by sintilimab were retrieved from CNKI,Wanfang,VIP,PubMed,and Embase databases,followed by summary analysis.Results:A total of 29 literatures were included,involving 29 patients:21 males(72.41%)and 8 females(27.59%),predominantly aged 50～69 years.ADR occurred as early as 1 hour and as late as 17 months after the first administration,with the majority(79.31%)appearing 2～8 months post-treatment.Manifestations included hypothyroidism,autoimmune diabetes,adrenocortical insufficiency,hypopituitarism,etc.After treatment,28 patients showed improved symptoms,while 1 patient had poor blood sugar control.Conclusion:The endocrine system ADR induced by sintilimab commonly occur in the middle-aged and elderly male patients with a wide time span.Therefore,in clinical treatment,medication monitoring should be strengthened to ensure the safety of patients'medication.关键词
信迪利单抗/内分泌系统/不良反应/病例分析/合理用药Key words
sintilimab/endocrine system/adverse reaction/case analysis/rational drug use分类
医药卫生
